# Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

> **NCT01393756** · PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 80 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Lenalidomide and R-CHOP

## Key facts

- **NCT ID:** NCT01393756
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-07
- **Final completion:** 2015-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393756, "Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01393756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*